Home> Products> Inhibitors> Levofloxacin-CAS 100986-85-4
price inquiry for CAS:100986-85-4, Product:Levofloxacin

Levofloxacin CAS: 100986-85-4

Category: Inhibitors
Product Name: Levofloxacin
Cat No: I000113
CAS No: 100986-85-4
Synonyms: (S)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-3,7-dihydro-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid
Molecular Formula: C18H20FN3O4
Molecular Weight: 361.4
SMILES: FC1=C(N2CCN(C)CC2)C(OC[C@H](C)N3C=C(C(O)=O)C4=O)=C3C4=C1
InChI: None
InChIKey: GSDSWSVVBLHKDQ-JTQLQIEISA-N
Solubility: DMSO 25 mg/mL; Water 11.2 mg/mL
Target: Antibiotic
Storage: Store at -20°C
CAS 100986-85-4,Levofloxacin
  • Description

Levofloxacin, a synthetic fluoroquinolone, is an antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. Target: Antibacterial 

Levofloxacin reduced bacterial load compared with placebo by 4.9-fold (95% confidence interval, 1.4-25.7; P=0.02) at day 7 but had no effect at any point on any marker of neutrophilic airway inflammation. In patients with a baseline bacterial load of more than 10(6) cfu/mL, levofloxacin treatment was associated with a 26.5% (95% confidence interval, 1.8%-51.3%; P=0.04) greater reduction in the percentage neutrophil count compared with placebo at day 7 [1]. Levofloxacin was found to significantly improve the clinical and microbiological parameters in CP individuals [2]. A 30-day course of levofloxacin does not significantly improve BK viral load reduction or allograft function when used in addition to overall reduction of immunosuppression. 

  • Spec

Appearance:Solid powder
Purity: > 98%

  • References


1:Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis patients. Van't Boveneind-Vrubleuskaya N, Seuruk T, van Hateren K, van der Laan T, Kosterink JGW, van der Werf TS, van Soolingen D, van den Hof S, Skrahina A, Alffenaar JC.Antimicrob Agents Chemother. 2017 May 15. pii: AAC.00343-17. doi: 10.1128/AAC.00343-17. [Epub ahead of print] PMID: 28507117
2:Electrocatalytic properties of N-doped graphite felt in electro-Fenton process and degradation mechanism of levofloxacin. Liu X, Yang D, Zhou Y, Zhang J, Luo L, Meng S, Chen S, Tan M, Li Z, Tang L.Chemosphere. 2017 May 6;182:306-315. doi: 10.1016/j.chemosphere.2017.05.035. [Epub ahead of print] PMID: 28501570
3:Application of Deep Eutectic Solvents in Hybrid Molecularly Imprinted Polymers and Mesoporous Siliceous Material for Solid-Phase Extraction of Levofloxacin from Green Bean Extract. Li X, Row KH.Anal Sci. 2017;33(5):611-617. doi: 10.2116/analsci.33.611. PMID: 28496066 Free Article
4:In Vitro Resistance Selection in Shigella flexneri by Azithromycin, Ceftriaxone, Ciprofloxacin, Levofloxacin, and Moxifloxacin. Allen GP, Harris KA.Antimicrob Agents Chemother. 2017 May 8. pii: AAC.00086-17. doi: 10.1128/AAC.00086-17. [Epub ahead of print] PMID: 28483960
5:[Levofloxacin-based triple therapy versus bismuth-based quadruple therapy in the treatment of Helicobacter pylori as the rescue therapy: a meta analysis]. Zhang M, Chen CY, Wang XT, Lyu B.Zhonghua Nei Ke Za Zhi. 2017 May 1;56(5):368-374. doi: 10.3760/cma.j.issn.0578-1426.2017.05.013. Chinese. PMID: 28460509
6:Easy-Assessment of Levofloxacin and Minocycline in Relevant Biomimetic Media by HPLC-UV Analysis. Matos AC, Pinto RV, Bettencourt AF.J Chromatogr Sci. 2017 Apr 24:1-9. doi: 10.1093/chromsci/bmx033. [Epub ahead of print] PMID: 28444354
7:Cost-effectiveness analysis of oral versus intravenous drip infusion of levofloxacin in the treatment of acute lower respiratory tract infection in Chinese elderly patients. Zhang L, Hu P.Clin Interv Aging. 2017 Apr 12;12:673-678. doi: 10.2147/CIA.S127009. eCollection 2017. PMID: 28442897 Free PMC Article
8:Experimental study on the influence of low-frequency and low-intensity ultrasound on the permeability of the Mycobacterium smegmatis cytoderm and potentiation with levofloxacin. Dong Y, Su H, Jiang H, Zheng H, Du Y, Wu J, Li D.Ultrason Sonochem. 2017 Jul;37:1-8. doi: 10.1016/j.ultsonch.2016.12.024. Epub 2016 Dec 19. PMID: 28427611
9:Dry powders for the inhalation of ciprofloxacin or levofloxacin combined with a mucolytic agent for cystic fibrosis patients. Akdag Cayli Y, Sahin S, Buttini F, Balducci AG, Montanari S, Vural I, Oner L.Drug Dev Ind Pharm. 2017 Apr 27:1-12. doi: 10.1080/03639045.2017.1318902. [Epub ahead of print] PMID: 28420285
10:Levofloxacin-Induced Acute Immune-Mediated Thrombocytopenia of Rapid-Onset. Shih AW, Lam AS, Warkentin TE.J Pharm Pract. 2017 Jan 1:897190017702306. doi: 10.1177/0897190017702306. [Epub ahead of print] PMID: 28403679


price inquiry for CAS:100986-85-4, Product:Levofloxacin